Clincosm LogoSign in Get a demo

Opioid-induced Hyperalgesia After Remifentanil Infusion

Sponsor
Oslo University Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT01702389
Collaborator
(none)
16
Enrollment
1
Location
1
Arm
2
Duration (Months)
8
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Remifentanil is a rapid-acting opioid which has been widely used in pain treatment during surgery for the last 15 years 1. Remifentanil is rapidly eliminated (minutes) from the body after end of infusion, and this makes it easily manageable compared to other opioids. However, there are both experimental and clinical studies indicating that remifentanil, after end of infusion, triggers increased pain sensation and increased opioid consumption post-operatively. Increased post-operative opioid consumption should be avoided due to the adverse effects of these drugs (nausea/vomiting, pruritus, dizziness, fatigue and reduced respiratory rate). Thus, it's important to investigate relevant strategies to avoid the increased pain sensation (opioid-induced hyperalgesia = hypersensitivity to pain stimuli) after end of infusion of remifentanil after surgery. Several experimental and clinical trials have been conducted in this field. Ketamine has been shown to block this effect, but its adverse effect profile (i.a. hallucinations) makes it not suitable in normal clinical use. In a study of healthy volunteers, it has been demonstrated that parecoxib (a COX-2 selective NSAID) can prevent remifentanil-induced hyperalgesia. Our group has previously shown that a relatively COX-1 selective NSAID (ketorolac) can prevent hyperalgesia in an experimental pain model.

This is of interest since NSAIDs are frequently administered as premedication before surgery. There are several disadvantages associated with the use of COX-2 inhibitors, e.g. the risk of myocardial infarction after long-term use (> 1 year), and potentially reduced bone healing after orthopedic surgery. However, this has not been shown with short-term use (days/week). The disadvantages associated with the use of e.g. ketorolac (a COX-1 inhibitor) are i.a. increased bleeding tendency, which is unfavourable for the surgeon, and increased risk of gastric ulcer. Therefore, it is of interest to investigate other ways of preventing opioid-induced hyperalgesia. In a recent animal study it has been shown that gradual dose reduction of remifentanil (vs. abrupt withdrawal of a relatively high remifentanil dose) can prevent the development of hyperalgesia after end of infusion. In this study we will i.a. investigate whether this is also the case in humans. In this new model, the study participants will get remifentanil infusion with two different dose reduction regimes: gradual reduction or abrupt withdrawal.

Condition or Disease Intervention/Treatment Phase
Phase 4

Study Design

Study Type:
Interventional
Actual Enrollment :
16 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Can Opioid-induced Hyperalgesia be Prevented by Gradual Dose Reduction vs. Abrupt Withdrawal of Remifentanil?
Study Start Date :
Oct 1, 2012
Actual Primary Completion Date :
Dec 1, 2012
Actual Study Completion Date :
Dec 1, 2012

Arms and Interventions

Arm Intervention/Treatment
Experimental: Remifentanil

The study has only one arm. Same group of volunteers will receive remifentanil infusion with abrupt withdrawal, remifentanil infusion with gradual dose reduction and saline infusion at three separate trials.

Drug: Remifentanil
Other Names:
  • Ultiva

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Hyperalgesia measured by numeric rating scale for pain [3 weeks]

      Two pain models will be used - a heat-pain and a cold-pain model. Testing will be done before, during and after remifentanil infusion. NRS (Numeric rating Scale) will be used for pain scoring. Heat model: A computer-controlled Medoc ATS Thermal stimulator (3 x 3 cm) is applied to the left volar forearm at pre-defined areas. Cold model: In the cold test the study participant should keep his right hand in circulating cold water (3 ̊C) in up to 90 seconds. The pain models will be applied during three separate trials using remifentanil infusion with abrupt withdrawal, remifentanil infusion with gradual withdrawal and saline infusion(placebo).

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 60 Years
    Sexes Eligible for Study:
    Male
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    • Male

    • Age 18-60

    • Body mass index 17-30

    • Healthy volunteers

    Exclusion Criteria:

    • Use of medication; alternative medicine

    • Substance abuse

    • Allergies towards medication used in the study

    • Participation in other clinical studies the previous 6 months

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Oslo University Hospital Oslo Norway 0424

    Sponsors and Collaborators

    • Oslo University Hospital

    Investigators

    • Principal Investigator: Marlin Comelon, MD, Oslo UH

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Marlin Comelon, Principal Investigator, Oslo University Hospital
    ClinicalTrials.gov Identifier:
    NCT01702389
    Other Study ID Numbers:
    • 2011/1639
    • 2011-002734-39
    • 11/14666
    First Posted:
    Oct 8, 2012
    Last Update Posted:
    Oct 29, 2014
    Last Verified:
    Oct 1, 2014
    Keywords provided by Marlin Comelon, Principal Investigator, Oslo University Hospital
    opioid induced hyperalgesia
    Pain
    Postoperative pain
    Hyperalgesia
    Additional relevant MeSH terms:
    Hyperalgesia
    Remifentanil

    Study Results

    No Results Posted as of Oct 29, 2014